文献速递主动脉疾病外周动脉疾病血液透析通路

原位腔内移植物治疗动脉与移植物感染

"In situ" endografting in the treatment of arterial and graft infections.
PubMed 文献 · J Vasc Surg · 2017-03-27

结果显示腔内移植物可有效控制各部位出血,短期结局良好,但致命感染相关并发症有报道,需长期 definitive 方案。尚无学会指南。

要点

  • 腔内移植物可用于治疗真菌性动脉瘤、主动脉肠瘘、主动脉支气管瘘及感染性假性动脉瘤。
  • 短期结局良好,但停用抗生素后致命感染相关并发症有报道。
  • 预计寿命<6个月者通常无需进一步干预,>6个月者应考虑更根治手术。

核心结论

  • 腔内移植物仍是治疗真菌性动脉瘤、主动脉食管瘘、主动脉支气管瘘及解剖或技术难以到达部位感染性假性动脉瘤的重要可行选择。
  • 短期结局良好,但致命感染相关并发症尤其停用抗生素后有报道,需长期更根治计划。

研究设计与样本

  • 综述限于原发和继发性细菌或病毒性动脉感染患者,伴或不伴瘘形成,以及旁路移植物和动静脉通路感染。

主要发现

  • 腔内移植物已成功应用于真菌性动脉瘤、主动脉肠瘘、主动脉支气管瘘和动脉输尿管瘘及感染继发动静脉吻合口出血。
  • 多处报告表明所有部位均能成功控制出血,短期结局良好。
  • 致命感染相关并发症尤其停用抗生素后有充分报道。

关键数值与推荐

  • 尚无学会指南。
  • 预计寿命<6个月患者通常无需进一步干预。
  • 预计寿命>6个月患者应仔细考虑更根治手术。
  • 感染区域接受腔内移植物者强烈推荐终身适当抗生素治疗。

临床怎么用

  • 对解剖或技术难以到达、活动性出血或破裂的动脉及移植物感染患者,可考虑原位腔内移植物控制出血。
  • 根据预计寿命决定是否需进一步根治手术,感染区域置入移植物者应终身使用适当抗生素。

局限性

  • 无学会指南,证据基于文献综述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endografts (eg, aortic aneurysm device or covered stent) are increasingly being used to temporize or treat arterial and graft infections in inaccessible areas, in patients with compromised anatomy, or in the presence of active bleeding or rupture. This summary examines the evidence for "in situ" endografting in the treatment these conditions. METHODS: A two-level search strategy of the literature (MEDLINE, PubMed, Google Scholar, and The Cochrane Library) was performed for relevant articles listed between January 2000 and December 2015. The review was confined to patients with primary and secondary bacterial or viral arterial infections, with or without fistulization and infection of bypass grafts and arteriovenous accesses. For the purposes of this summary, endografts can be considered to be an aortic aneurysm device or a covered stent. RESULTS: There are no societal guidelines. Endografts have been successfully applied to mycotic arterial aneurysms, aortoenteric, aortobronchial, and arterioureteric fistulae, and to anastomotic bleeds secondary to infection. Multiple reports indicate success at the control of hemorrhage in all locations. Short-term outcomes are good, but fatal infection-related complications, especially if antibiotic therapy is halted, are well reported and necessitate a more definitive plan for the long term. CONCLUSIONS: Stent grafts remain an important and viable option for the treatment of mycotic aneurysms, aortoesophageal and aortobronchial fistulae, and infected pseudoaneurysms in anatomically or technically inaccessible locations. In patients with a short life span (<6 months), no further intervention is generally required. In patients with a predicted life span >6 months, careful consideration should be given to a more definitive procedure. Life-long appropriate antibiotic therapy is strongly recommended for any patient receiving an endograft in an infected field.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Haidar GM, Hicks TD, Strosberg DS, et al. "In situ" endografting in the treatment of arterial and graft infections. J Vasc Surg. 2017. PMID: 28359717. doi:10.1016/j.jvs.2016.12.134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。